Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEBiotechnology
-$0.26 today
- Market cap
- $761.36M
- Beta
- 1.60
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.98
Volume 1.11M
Average 1.02M
Income Statement
Follow revenue through to earnings.
Revenue
$123.67M
FY 2025 · Annual
+63.5% YoYOperating Income
-$54.21M
FY 2025 · Annual
Net Income
-$38.63M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 75.62M | 123.67M |
| Cost of Revenue | 0 | 0 | 6.22M | 8.12M | 8.36M |
| Gross Profit | 0 | 0 | (6.22M) | 67.5M | 115.32M |
| Gross Margin | — | — | — | 89.3% | 93.2% |
| Research & Development | 57.16M | 85.06M | 105.05M | 121.56M | 141.5M |
| Selling, General & Admin | 15.73M | 27.32M | 32.04M | 35.17M | 36.38M |
| Operating Expenses | 72.88M | 112.38M | 137.09M | 148.61M | 169.52M |
| Depreciation & Amortization | 2.13M | 3.75M | 6.22M | 8.12M | 8.36M |
| EBITDA | (71.83M) | (100.99M) | (128.79M) | (62.01M) | (31.37M) |
| EBITDA Margin | — | — | — | -82.0% | -25.4% |
| Operating Income | (72.88M) | (112.38M) | (143.31M) | (81.11M) | (54.21M) |
| Operating Margin | — | — | — | -107.3% | -43.8% |
| Interest Income | 46K | 3.76M | 9.33M | 10.57M | 12.94M |
| Interest Expense | 0 | 3.76M | 0 | 0 | 0 |
| Other Income / Expenses | (1.08M) | 3.88M | 8.3M | 10.98M | 14.49M |
| Income Before Tax | (73.96M) | (108.5M) | (135.01M) | (70.13M) | (39.72M) |
| Pre-Tax Margin | — | — | — | -92.7% | -32.1% |
| Income Tax Expense | 0 | 0 | 338K | 2.57M | (1.1M) |
| Net Income | (73.96M) | (108.5M) | (135.35M) | (72.7M) | (38.63M) |
| Net Margin | — | — | — | -96.1% | -31.2% |
| EPS (Basic) | (1.59) | (2.30) | (2.63) | (0.98) | (0.46) |
| EPS (Diluted) | (1.59) | (2.30) | (2.63) | (0.98) | (0.46) |
| 46.54M | 47.23M | 51.4M | 73.91M | 83.07M | |
| 46.54M | 47.23M | 51.4M | 73.91M | 83.07M |
GLUE Earnings Waterfall · TTM
NASDAQ:GLUE · Revenue to Net Income
Key Ratios
Analysis
$43.0M of revenue converted into -$130.0M of net income for the selected period. Gross margin is 88.0% and net margin is -745.3%, showing how much revenue survives after costs and taxes. EPS is $-1.86, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 8-K | Current report | Oct 1, 2026 | |
| 8-K | Current report | Sep 8, 2026 |
How much revenue does GLUE generate?
Monte Rosa Therapeutics, Inc. (GLUE) reported $123.67M of revenue in fiscal 2025.
Is GLUE profitable?
Monte Rosa Therapeutics, Inc. (GLUE) reported -$38.63M of net income, with a net margin of -31.2%.
Continue the stock analysis
Jump to another research area for this company.